keyword
https://read.qxmd.com/read/38633747/derangements-of-immunological-proteins-in-hiv-associated-diffuse-large-b-cell-lymphoma-the-frequency-and-prognostic-impact
#1
JOURNAL ARTICLE
Jenifer Vaughan, Moosa Patel, Melinda Suchard, Maemu Gededzha, Heena Ranchod, Wayne Howard, Tracy Snyman, Tracey Wiggill
INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of B-cells frequently encountered among people living with HIV. Immunological abnormalities are common in immunocompetent individuals with DLBCL, and are often associated with poorer outcomes. Currently, data on derangements of immunological proteins, such as cytokines and acute phase reactants, and their impact on outcomes in HIV-associated DLBCL (HIV-DLBCL) is lacking. This study assessed the levels and prognostic relevance of interleukin (IL)-6, IL-10 and Transforming Growth Factor Beta (TGFβ), the acute phase proteins C-reactive protein (CRP) and ferritin; serum free light chains (SFLC) (elevation of which reflects a prolonged pro-inflammatory state); and the activity of the immunosuppressive enzyme Indoleamine 2,3-dioxygenase (IDO)in South African patients with DLBCL...
2024: Frontiers in Cellular and Infection Microbiology
https://read.qxmd.com/read/38633575/marginal-zone-lymphoma-international-prognostic-index-a-unifying-prognostic-index-for-marginal-zone-lymphomas-requiring-systemic-treatment
#2
JOURNAL ARTICLE
Luca Arcaini, Côme Bommier, Juan Pablo Alderuccio, Michele Merli, Nicole Fabbri, Maria Elena Nizzoli, Matthew J Maurer, Vittoria Tarantino, Simone Ferrero, Sara Rattotti, Annalisa Talami, Roberta Murru, Arushi Khurana, Raphael Mwangi, Marina Deodato, Emanuele Cencini, Francesca Re, Carlo Visco, Andrew L Feldman, Brian K Link, Marcia Torresan Delamain, Michele Spina, Ombretta Annibali, Alessandro Pulsoni, Andrés J M Ferreri, Caterina Cecilia Stelitano, Elsa Pennese, Thomas M Habermann, Luigi Marcheselli, Sunwoo Han, Isildinha M Reis, Marco Paulli, Izidore S Lossos, James R Cerhan, Stefano Luminari
BACKGROUND: Marginal zone lymphomas (MZL), comprised of three unique but related subtypes, lack a unifying prognostic score applicable to all the patients in need for systemic chemotherapy and/or immunotherapy. METHODS: Patients from the prospective NF10 study (NCT02904577) with newly diagnosed MZL and receiving frontline systemic therapy at diagnosis or after observation were used to train a prognostic model. The primary endpoint was progression-free survival (PFS) from start of treatment...
June 2024: EClinicalMedicine
https://read.qxmd.com/read/38632203/adverse-events-of-nivolumab-plus-ipilimumab-versus-nivolumab-plus-cabozantinib-a-real-world-pharmacovigilance-study
#3
JOURNAL ARTICLE
Yurie Oka, Jun Matsumoto, Tatsuaki Takeda, Naohiro Iwata, Takahiro Niimura, Aya Fukuma Ozaki, Kensuke Bekku, Hirofumi Hamano, Motoo Araki, Keisuke Ishizawa, Yoshito Zamami, Noritaka Ariyoshi
BACKGROUND: No head-to-head clinical trials have compared the differences in adverse events (AEs) between nivolumab plus ipilimumab (NIVO-IPI) and nivolumab plus cabozantinib (NIVO-CABO) in the treatment of metastatic renal cell carcinoma (mRCC). AIM: We analysed the two largest real-world databases, the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the World Health Organization's VigiBase, to elucidate the differences in AEs between NIVO-IPI and NIVO-CABO...
April 17, 2024: International Journal of Clinical Pharmacy
https://read.qxmd.com/read/38628940/a-combined-methodological-approach-to-characterize-pig-farming-and-its-influence-on-the-occurrence-of-interactions-between-wild-boars-and-domestic-pigs-in-corsican-micro-regions
#4
JOURNAL ARTICLE
Liane Dupon, Bastien Trabucco, Facundo Muñoz, François Casabianca, François Charrier, Morgane Laval, Ferran Jori
The pig sector in Corsica is based by a wide range of farming systems, mainly characterized on traditional extensive practices, which favor contacts between domestic and wild individuals. These contacts are suspected to influence the maintenance and the transmission of shared infectious diseases between both populations. Therefore, it is important to develop methods that allow to understand and anticipate their occurrence. Modeling these interactions requires accurate data on the presence, location and use of land on pig farms and farming practices, but such data are often unavailable, incomplete or outdated...
2024: Frontiers in Veterinary Science
https://read.qxmd.com/read/38625495/comparison-of-efficacy-and-safety-of-pd-1-pd-l1-combination-therapy-in-first-line-treatment-of-advanced-nsclc-an-updated-systematic-review-and-network-meta-analysis
#5
JOURNAL ARTICLE
Yanqing Yang, Wei Chen, Lixian Dong, Lian Duan, Pengfei Gao
BACKGROUND: The use of immune checkpoint inhibitors has led to an increase in randomized controlled trials exploring various first-line combination treatment regimens. With the introduction of new PD-1/PD-L1 inhibitors, there are now more clinical options available. For the first time, the AK105 monoclonal antibody Penpulimab, developed in China, was included. The AK105-302 Phase III trial studied the efficacy and safety of Penpulimab combined with chemotherapy in patients with advanced or metastatic squamous NSCLC...
April 16, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38620092/reassessing-the-chronic-lymphocytic-leukemia-international-prognostic-index-in-the-era-of-targeted-therapies
#6
JOURNAL ARTICLE
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf, Anna-Maria Fink, Moritz Fürstenau, Nadine Kutsch, Florian Simon, Valentin Goede, Manuela A Hoechstetter, Carsten Utoft Niemann, Caspar da Cunha-Bang, Arnon P Kater, Julie Dubois, Michael Gregor, Philipp B Staber, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael J Hallek
We evaluated the prognostic value of the Chronic Lymphocytic Leukemia International Prognostic Index (CLL-IPI) using a pooled dataset of CLL-patients treated first-line with targeted drugs (N=991) or chemoimmunotherapy (N=1,256). With a median observation time of 40.5 months, the 3-year progression-free survival (PFS)-rates for targeted drug-treated patients varied by CLL-IPI risk group: 96.5% (low), 87.6% (intermediate), 82.4% (high), and 78.7% (very high). Differences between consecutive CLL-IPI risk groups were observed for intermediate vs...
April 15, 2024: Blood
https://read.qxmd.com/read/38619488/the-impact-of-race-and-ethnicity-on-diffuse-large-b-cell-lymphoma-outcomes-within-the-veterans-health-administration-vha
#7
JOURNAL ARTICLE
Andrew Ta, Supreet Kaur, Michael Mader, Kathleen Franklin, Madison Williams, Ryan Williams, Jean-Pierre Blaize, Amna Naqvi, Snegha Ananth, Michael Song, Brian Oliver Warnecke, Abhishek Pandya, Lakene Raissa Djoufack Djoumessi, Phillip Nazarewicz, Manuel Espinoza-Gutarra, Kana Tai Lucero, Jennifer Whitehead, Alaq Al-Abayechi, Lauren Boyle, Sophia Lee, Gabriel Roman Souza, Esteban Toro Velez, Ian Mines, Zohra Nooruddin
We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 patients who met inclusion criteria were predominantly male (97%) and white (75%). Median age of diagnosis for Black patients was 63 years vs 69 years for the entire cohort ( p  < 0.001). However, patients in each race/ethnicity subgroup presented with similar rates of stage I/II and III/IV disease, IPI score, cell of origin and HIT status...
April 15, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38604793/-efficacy-and-safety-analysis-of-p-gemdox-regimen-and-stratified-prognosis-in-patients-with-early-extranodal-nk-t-cell-lymphoma
#8
JOURNAL ARTICLE
T Y Xing, W T Wang, H R Shen, J Z Wu, H Yin, Y Li, L Wang, J H Liang, J Y Li, W Xu
Objective: To assess the efficacy, safety, and related prognostic factors associated with the P-GemDOx regimen as a first-line treatment for patients with early-stage extranodal natural killer (NK) /T cell lymphoma (ENKTL) . Methods: A retrospective analysis was performed on sixty early-stage ENKTL patients treated with the P-GemDOx regimen who were admitted to the First Affiliated Hospital of Nanjing Medical University between August 2015 and May 2021. The Chi-square test or Fisher's exact test was used to compare group differences, and the Log-rank test was used to compare the differences in survival...
February 14, 2024: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://read.qxmd.com/read/38604163/clinical-characteristics-and-prognostic-analysis-of-primary-extranodal-non-hodgkin-lymphoma-of-the-head-and-neck
#9
JOURNAL ARTICLE
Jiamu Lv, Yining Jiang, Tingting Yu, Shengrui Gao, Wanzhong Yin
OBJECTIVE: Primary extranodal non-Hodgkin's lymphoma (PE-NHL) of the head and neck is the second common site of extranodal lymphoma, accounting for approximately one-third of all extranodal non-Hodgkin's lymphoma (E-NHL). However, in recent years, large-scale PE-NHL case studies in China and worldwide are rare and not comprehensive enough. This work analyzed the clinical manifestations, pathological features, immunophenotypes and diagnosis of PE-NHL, as well as the factors affecting the treatment and prognosis...
April 5, 2024: Aging
https://read.qxmd.com/read/38601181/assessment-and-prognostic-significance-of-a-serum-cytokine-panel-in-diffuse-large-b%C3%A2-cell-lymphoma
#10
JOURNAL ARTICLE
Shufang Xie, Lifen Zhu, Lei Wang, Shibing Wang, Xiangmin Tong, Wanmao Ni
The objective of the present study was to assess the levels of circulating cytokines in patients with diffuse large B-cell lymphoma (DLBCL), and to examine the associations between the cytokine levels, clinicopathological manifestations and patient prognosis. The study enrolled 49 patients with DLBCL, 11 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and 67 healthy controls from Zhejiang Provincial People's Hospital (Hangzhou, China) between January 2017 and January 2020. The serum levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IL-17, tumor necrosis factor (TNF)-α and interferon (IFN)-γ were measured using flow cytometry...
May 2024: Oncology Letters
https://read.qxmd.com/read/38595841/predictive-value-of-corrected-18-f-fdg-pet-ct-baseline-parameters-for-primary-dlbcl-prognosis-a-single-center-study
#11
JOURNAL ARTICLE
Min Li, Jianpeng Liu, Fangfei Liu, Rongbin Lv, Haowei Bai, Shuyong Liu
Objective  The purpose of this study was to evaluate the prognostic significance of corrected baseline metabolic parameters in fluorodeoxyglucose positron emission tomography imaging ( 18 F-FDG PET/CT) for 3-year progression-free survival (PFS) in patients with primary diffuse large B cell lymphoma (DLBCL). Patients and Methods  Retrospective clinical and pathological data were collected for 199 patients of DLBCL diagnosed between January 2018 and January 2021. All patients underwent 18 F-FDG PET/CT scans without any form of treatment...
March 2024: World Journal of Nuclear Medicine
https://read.qxmd.com/read/38595337/a-nomogram-model-based-on-the-inflammation-immunity-nutrition-score-iins-and-classic-clinical-indicators-for-predicting-prognosis-in-extranodal-natural-killer-t-cell-lymphoma
#12
JOURNAL ARTICLE
Yanxia He, Zhumei Luo, Haoqing Chen, Liqing Ping, Cheng Huang, Yan Gao, Huiqiang Huang
BACKGROUND: Systemic inflammation, immunity, and nutritional status are closely related to patients' outcomes in several kinds of cancers. This study aimed to establish a new nomogram based on inflammation-immunity-nutrition score (IINS) to predict the prognosis of extranodal natural killer/T-cell lymphoma (ENKTL) patients. METHODS: The clinical data of 435 patients with ENTKL were retrospectively reviewed and randomly assigned to training cohort (n=305) and validation cohort (n=131) at a ratio of 7:3...
2024: Journal of Inflammation Research
https://read.qxmd.com/read/38594876/outcome-and-feasibility-of-radiotherapy-bridging-in-large-b-cell-lymphoma-patients-receiving-cd19-car-t-in-the-uk
#13
JOURNAL ARTICLE
A Kuhnl, C Roddie, A A Kirkwood, S Chaganti, J Norman, S Lugthart, W Osborne, A Gibb, C Gonzalez Arias, A Latif, B Uttenthal, F Seymour, C Jones, D Springell, J L Brady, T Illidge, A Stevens, E Alexander, L Hawley, N O'Rourke, C Bedi, R Prestwich, J Frew, D Burns, M O'Reilly, R Sanderson, S Sivabalasingham, N G Mikhaeel
Radiotherapy (RT) has potential synergistic effects with chimeric antigen receptor (CAR) T but is not widely used as bridging therapy due to logistical challenges and lack of standardised protocols. We analysed RT bridging in a multicentre national cohort of large B-cell lymphoma patients approved for 3L axicabtagene ciloleucel or tisagenlecleucel across 12 UK centres. Of 763 approved patients, 722 were leukapheresed, 717 had data available on bridging therapy. 169/717 (24%) received RT bridging, 129 as single modality and 40 as combined modality treatment (CMT)...
April 9, 2024: British Journal of Haematology
https://read.qxmd.com/read/38589958/swine-acute-diarrhea-syndrome-coronavirus-nsp1-suppresses-ifn-%C3%AE-1-production-by-degrading-irf1-via-ubiquitin-proteasome-pathway
#14
JOURNAL ARTICLE
Chunhui Zhong, Gaoli She, Yukun Zhao, Yufang Liu, Jingmin Li, Xiaona Wei, Zexin Chen, Keyu Zhao, Zhiqing Zhao, Zhichao Xu, Hao Zhang, Yongchang Cao, Chunyi Xue
Swine acute diarrhea syndrome coronavirus (SADS-CoV) is a novel porcine enteric coronavirus that causes acute watery diarrhea, vomiting, and dehydration in newborn piglets. The type III interferon (IFN-λ) response serves as the primary defense against viruses that replicate in intestinal epithelial cells. However, there is currently no information available on how SADS-CoV modulates the production of IFN-λ. In this study, we utilized IPI-FX cells (a cell line of porcine ileum epithelium) as an in vitro model to investigate the potential immune evasion strategies employed by SADS-CoV against the IFN-λ response...
April 8, 2024: Veterinary Research
https://read.qxmd.com/read/38554189/the-effect-of-metabolic-syndrome-on-prognosis-of-diffuse-large-b-cell-lymphoma
#15
JOURNAL ARTICLE
Wenjing Xiong, Liru Li, Xue Hui, Yue Liu, Hongbin Li, Yue Zhang, Shu Zhao
PURPOSE: Metabolic syndrome (MetS), characterized by insulin resistance, is closely associated with the prognosis of various cancer types, but has not been reported in diffuse large B-cell lymphoma (DLBCL). The aim of this study is to examine how other clinicopathological variables and the MetS influence the prognosis of DLBCL. METHODS: Clinical and pathological data were collected from 319 patients with DLBCL who were admitted to our hospital between January 2012 and December 2020...
March 30, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38553068/risk-factors-for-premature-rupture-of-membranes-in-pregnant-women-a-systematic-review-and-meta-analysis
#16
JOURNAL ARTICLE
Danna Lin, Bing Hu, Yuqi Xiu, Ruiting Ji, Huifang Zeng, Hongyan Chen, Yanchun Wu
OBJECTIVE: To identify risk factors for premature rupture of membranes (PROM) in pregnant women. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Web of Science, PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, Chinese Scientific Journal Database (VIP) and China Biology Medicine Disc were searched from inception to October 2022. ELIGIBILITY CRITERIA: Cross-sectional, case-control and cohort studies published in English or Chinese that reported the risk factors for PROM were eligible for inclusion...
March 29, 2024: BMJ Open
https://read.qxmd.com/read/38546551/neoadjuvant-dual-checkpoint-inhibitors-vs-anti-pd1-therapy-in-high-risk-resectable-melanoma-a-pooled-analysis
#17
JOURNAL ARTICLE
Ankit Mangla, Chanmi Lee, Matthew M Mirsky, Margaret Wang, Luke D Rothermel, Richard Hoehn, Jeremy S Bordeaux, Bryan T Carrol, Jason Theuner, Shawn Li, Pingfu Fu, John M Kirkwood
IMPORTANCE: Despite the clear potential benefits of neoadjuvant therapy, the optimal neoadjuvant regimen for patients with high-risk resectable melanoma (HRRM) is not known. OBJECTIVE: To compare the safety and efficacy of dual checkpoint inhibitors with anti-programmed cell death protein-1 (anti-PD1) therapy in a neoadjuvant setting among patients with HRRM. DESIGN, SETTING, AND PARTICIPANTS: In this pooled analysis of clinical trials, studies were selected provided they investigated immune checkpoint inhibitor treatment, were published between January 2018 and March 2023, and were phase 1, 2, or 3 clinical trials...
March 28, 2024: JAMA Oncology
https://read.qxmd.com/read/38545024/clinical-utility-of-cll-ipi-scoring-system-in-pakistani-chronic-lymphocytic-patients-a-single-center-experience
#18
JOURNAL ARTICLE
Aisha Hameed, Nadia Sajid, Muhammad Fayyaz, Shagufta Khaliq
OBJECTIVES: To determine validity of the CLL International prognostic index (IPI) scoring system in Pakistani chronic lymphocytic leukemia patients, as the validity and universal applicability of various prognostic scoring systems such as the CLL-IPI remains a challenge, particularly in under-developed countries like Pakistan. METHODS: This prospective single center study was conducted at Department of Hematology, University of Health Sciences, Lahore and included sixty patients with CLL diagnosed between July, 2019 to July, 2022...
2024: Pakistan Journal of Medical Sciences Quarterly
https://read.qxmd.com/read/38529375/case-report-a-case-of-metastatic-brafv600-mutated-melanoma-with-heart-failure-treated-with-immune-checkpoint-inhibitors-and-braf-mek-inhibitors
#19
Aya Nishizawa, Misaki Kawakami, Yasuyuki Kitahara
BACKGROUND: Novel therapies, immune checkpoint inhibitors (ICIs), and BRAF/MEK inhibitors (BRAFi/MEKi) provide unprecedented survival benefits for patients with advanced melanoma. However, the management of drug-induced adverse events is problematic for both agents and, although rare, can cause serious cardiac dysfunction. CASE REPORT: A 42-year-old male patient with no significant medical history noticed a fading dark brown patch on his left anterior chest, which had been there for 20 years, after his second coronavirus disease 2019 (COVID-19) vaccination...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38516346/diving-into-cdc-pregnancy-data-in-the-united-states-longitudinal-study-and-interactive-application
#20
JOURNAL ARTICLE
Andrea O Clark-Sevilla, Yun C Lin, Arnav Saxena, Qi Yan, Ronald Wapner, Anita Raja, Itsik Pe'er, Ansaf Salleb-Aouissi
OBJECTIVE: Preterm birth (PTB) is a major determinant of neonatal mortality, morbidity, and childhood disability. In this article, we present a longitudinal analysis of the risk factors associated with PTB and how they have varied over the years: starting from 1968 when the CDC first started, reporting the natality data, up until 2021. Along with this article, we are also releasing an RShiny web application that will allow for easy consumption of this voluminous dataset by the research community...
April 2024: JAMIA Open
keyword
keyword
8788
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.